NO324766B1 - Anvendelse av modifisert CD55-protein og modifisert CD97-protein for fremstilling av medikamenter mot immunforsvarsrelaterte sykdommer samt vektorer og celler som danner slike proteiner - Google Patents
Anvendelse av modifisert CD55-protein og modifisert CD97-protein for fremstilling av medikamenter mot immunforsvarsrelaterte sykdommer samt vektorer og celler som danner slike proteiner Download PDFInfo
- Publication number
- NO324766B1 NO324766B1 NO19990581A NO990581A NO324766B1 NO 324766 B1 NO324766 B1 NO 324766B1 NO 19990581 A NO19990581 A NO 19990581A NO 990581 A NO990581 A NO 990581A NO 324766 B1 NO324766 B1 NO 324766B1
- Authority
- NO
- Norway
- Prior art keywords
- protein
- modified
- binding
- antibody
- use according
- Prior art date
Links
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 title claims abstract description 119
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 title claims abstract description 118
- 102100025680 Complement decay-accelerating factor Human genes 0.000 title claims abstract description 84
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 title claims abstract description 84
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 13
- 229940079593 drug Drugs 0.000 title claims description 13
- 201000010099 disease Diseases 0.000 title claims description 12
- 108090000623 proteins and genes Proteins 0.000 title claims description 10
- 102000004169 proteins and genes Human genes 0.000 title claims description 9
- 239000013598 vector Substances 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 65
- 230000024203 complement activation Effects 0.000 claims abstract description 19
- 230000003993 interaction Effects 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 230000000903 blocking effect Effects 0.000 claims description 14
- 230000001900 immune effect Effects 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 230000003394 haemopoietic effect Effects 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims description 2
- 210000004880 lymph fluid Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 abstract description 34
- 210000000265 leukocyte Anatomy 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 6
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 abstract description 5
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 abstract description 5
- 230000004913 activation Effects 0.000 abstract description 5
- 239000000427 antigen Substances 0.000 abstract description 5
- 102000036639 antigens Human genes 0.000 abstract description 5
- 108091007433 antigens Proteins 0.000 abstract description 5
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 abstract description 5
- 230000037361 pathway Effects 0.000 abstract description 5
- 102100028927 Secretin receptor Human genes 0.000 abstract description 3
- 230000002950 deficient Effects 0.000 abstract description 3
- 108700027603 secretin receptor Proteins 0.000 abstract description 3
- 108010045403 Calcium-Binding Proteins Proteins 0.000 abstract description 2
- 102000005701 Calcium-Binding Proteins Human genes 0.000 abstract description 2
- 210000004698 lymphocyte Anatomy 0.000 abstract description 2
- 108091005465 peptide hormone receptors Proteins 0.000 abstract description 2
- 102000014187 peptide receptors Human genes 0.000 abstract description 2
- 238000002689 xenotransplantation Methods 0.000 abstract description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 abstract 1
- 108091006104 gene-regulatory proteins Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 description 15
- 108010029485 Protein Isoforms Proteins 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 9
- 239000003446 ligand Substances 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000013632 homeostatic process Effects 0.000 description 6
- 230000008105 immune reaction Effects 0.000 description 6
- 210000002437 synoviocyte Anatomy 0.000 description 6
- 108700024394 Exon Proteins 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 4
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 101100365087 Arabidopsis thaliana SCRA gene Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 101150105073 SCR1 gene Proteins 0.000 description 3
- 101100134054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NTG1 gene Proteins 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 102100026439 Adhesion G protein-coupled receptor E1 Human genes 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 102100031609 Complement C2 Human genes 0.000 description 2
- 108090000955 Complement C2 Proteins 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000718225 Homo sapiens Adhesion G protein-coupled receptor E1 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 101100406572 Arabidopsis thaliana ORTH1 gene Proteins 0.000 description 1
- 108010009575 CD55 Antigens Proteins 0.000 description 1
- 101150108282 Cd55 gene Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100037642 Elongation factor G, mitochondrial Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000880344 Homo sapiens Elongation factor G, mitochondrial Proteins 0.000 description 1
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 description 1
- 101000668170 Homo sapiens RNA-binding motif, single-stranded-interacting protein 2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 description 1
- 102100039690 RNA-binding motif, single-stranded-interacting protein 2 Human genes 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Paper (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96202244 | 1996-08-09 | ||
| PCT/NL1997/000462 WO1998006838A1 (en) | 1996-08-09 | 1997-08-11 | Methods and means for modifying complement activation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO990581D0 NO990581D0 (no) | 1999-02-08 |
| NO990581L NO990581L (no) | 1999-04-08 |
| NO324766B1 true NO324766B1 (no) | 2007-12-10 |
Family
ID=8224272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19990581A NO324766B1 (no) | 1996-08-09 | 1999-02-08 | Anvendelse av modifisert CD55-protein og modifisert CD97-protein for fremstilling av medikamenter mot immunforsvarsrelaterte sykdommer samt vektorer og celler som danner slike proteiner |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6328968B1 (de) |
| EP (1) | EP0920502B1 (de) |
| JP (1) | JP2001503248A (de) |
| AT (1) | ATE319824T1 (de) |
| AU (1) | AU733249B2 (de) |
| CA (1) | CA2263219A1 (de) |
| DE (1) | DE69735424T2 (de) |
| ES (1) | ES2260797T3 (de) |
| NO (1) | NO324766B1 (de) |
| PT (1) | PT920502E (de) |
| WO (1) | WO1998006838A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0938557B1 (de) * | 1996-10-25 | 2000-09-13 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit |
| GB9807520D0 (en) * | 1998-04-09 | 1998-06-10 | Univ Wales Medicine | Modified biological material |
| GB0227644D0 (en) * | 2002-11-27 | 2003-01-08 | Cancer Rec Tech Ltd | Specific binding members and uses thereof |
| EP1682710A4 (de) * | 2003-10-22 | 2006-12-20 | Polymer Group Inc | Belastbares netzgewirke |
| US20050112139A1 (en) * | 2003-10-23 | 2005-05-26 | Nmk Research, Llc | Immunogenic composition and method of developing a vaccine based on factor H binding sites |
| WO2006121445A2 (en) * | 2005-05-10 | 2006-11-16 | United States Of America Department Of Veteran's Affairs | Therapy of kidney diseases and multiorgan failure with mesenchymal stem cells and mesenchymal stem cell conditioned media |
| CN110627903B (zh) * | 2019-10-29 | 2021-09-21 | 河南大学 | 抗cd97单克隆抗体、其可变区与恒定区序列及应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69433745T2 (de) * | 1993-09-24 | 2005-05-19 | Washington University | Modifizierte, verkürzte regulatoren des komplementsystems |
-
1997
- 1997-08-11 EP EP97935896A patent/EP0920502B1/de not_active Expired - Lifetime
- 1997-08-11 DE DE69735424T patent/DE69735424T2/de not_active Expired - Fee Related
- 1997-08-11 AT AT97935896T patent/ATE319824T1/de not_active IP Right Cessation
- 1997-08-11 AU AU38698/97A patent/AU733249B2/en not_active Ceased
- 1997-08-11 PT PT97935896T patent/PT920502E/pt unknown
- 1997-08-11 JP JP50961598A patent/JP2001503248A/ja active Pending
- 1997-08-11 WO PCT/NL1997/000462 patent/WO1998006838A1/en active IP Right Grant
- 1997-08-11 ES ES97935896T patent/ES2260797T3/es not_active Expired - Lifetime
- 1997-08-11 US US09/242,161 patent/US6328968B1/en not_active Expired - Fee Related
- 1997-08-11 CA CA002263219A patent/CA2263219A1/en not_active Abandoned
-
1999
- 1999-02-08 NO NO19990581A patent/NO324766B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PT920502E (pt) | 2006-07-31 |
| ATE319824T1 (de) | 2006-03-15 |
| JP2001503248A (ja) | 2001-03-13 |
| CA2263219A1 (en) | 1998-02-19 |
| DE69735424D1 (de) | 2006-05-04 |
| EP0920502B1 (de) | 2006-03-08 |
| AU733249B2 (en) | 2001-05-10 |
| EP0920502A1 (de) | 1999-06-09 |
| US6328968B1 (en) | 2001-12-11 |
| ES2260797T3 (es) | 2006-11-01 |
| WO1998006838A1 (en) | 1998-02-19 |
| DE69735424T2 (de) | 2006-10-12 |
| NO990581L (no) | 1999-04-08 |
| NO990581D0 (no) | 1999-02-08 |
| AU3869897A (en) | 1998-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11384144B2 (en) | T cell receptor-like antibodies specific for a PRAME peptide | |
| US7452536B2 (en) | Methods of treating cancer by administering antibodies to CD200 | |
| US7902151B2 (en) | Methods and compositions for modulating immunity | |
| JP4463418B2 (ja) | Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用 | |
| US20020177191A1 (en) | Methods for treatment of asthmatic disorders | |
| US7589074B2 (en) | Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents | |
| MX2012000155A (es) | Receptores de celulas t. | |
| WO2001000810A1 (en) | Glycoprotein vi and uses thereof | |
| WO2002080968A1 (en) | Glycoprotein vi and uses thereof | |
| WO2000035483A1 (en) | Methods and products for regulating lectin complement pathway associated complement activation | |
| US7223729B2 (en) | Methods of treating allergy by administering a CD200 protein | |
| NO324766B1 (no) | Anvendelse av modifisert CD55-protein og modifisert CD97-protein for fremstilling av medikamenter mot immunforsvarsrelaterte sykdommer samt vektorer og celler som danner slike proteiner | |
| WO1998003551A1 (en) | Cd6 ligand | |
| NO303500B1 (no) | FremgangsmÕte for fremstilling av et terapeutisk aktivt vannl°selig, funksjonelt derivat av ICAM-1 samt rekombinant DNA-molekyl istand til Õ uttrykke et vannl°selig funksjonelt derivat av ICAM-1 | |
| Nasu et al. | α-galactosyl-mediated activation of porcine endothelial cells: studies on CD31 and VE-cadherin in adhesion and signaling | |
| MXPA99001388A (en) | Methods and means for modifying complement activation | |
| WO1998015626A2 (en) | Mutant ciita molecule and uses thereof | |
| EP2267029B1 (de) | Verfahren und Zusammensetzungen zur Behandlung von Entzündungskrankheiten unter Verwendung von Cadherin-11-modulierenden Agenzien | |
| TIMoTHY et al. | Receptor Function' |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |